 Marilee Wick
Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neprilysin | 3 | 2016 | 47 | 0.930 |
Why?
| | Evans Blue | 1 | 2018 | 7 | 0.620 |
Why?
| | Capillary Permeability | 1 | 2018 | 131 | 0.590 |
Why?
| | Blood Vessels | 1 | 2016 | 181 | 0.460 |
Why?
| | Airway Remodeling | 1 | 2010 | 58 | 0.340 |
Why?
| | Lung | 4 | 2016 | 3745 | 0.280 |
Why?
| | Phospholipases A | 1 | 2005 | 99 | 0.230 |
Why?
| | Cytosol | 1 | 2005 | 215 | 0.230 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2003 | 215 | 0.220 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 73 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 944 | 0.210 |
Why?
| | Trans-Activators | 1 | 2005 | 381 | 0.200 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1198 | 0.170 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 332 | 0.160 |
Why?
| | Transcription Factors | 3 | 2011 | 1628 | 0.160 |
Why?
| | Substance P | 1 | 2016 | 43 | 0.130 |
Why?
| | Doxycycline | 1 | 2016 | 56 | 0.130 |
Why?
| | Duodenum | 1 | 2016 | 71 | 0.130 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1030 | 0.120 |
Why?
| | Mice | 5 | 2018 | 16574 | 0.110 |
Why?
| | Transfection | 3 | 2005 | 891 | 0.100 |
Why?
| | Hypertension, Pulmonary | 3 | 2011 | 1747 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2016 | 2066 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.100 |
Why?
| | Animals | 7 | 2018 | 34487 | 0.100 |
Why?
| | Blotting, Western | 2 | 2010 | 1169 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 315 | 0.080 |
Why?
| | Cell Line | 3 | 2005 | 2736 | 0.080 |
Why?
| | Cell Division | 3 | 2009 | 777 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2010 | 365 | 0.070 |
Why?
| | Lung Neoplasms | 3 | 2005 | 2327 | 0.070 |
Why?
| | Pulmonary Circulation | 1 | 2009 | 417 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2508 | 0.070 |
Why?
| | Phospholipases A2 | 1 | 2005 | 79 | 0.060 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 56 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2005 | 89 | 0.060 |
Why?
| | Group IV Phospholipases A2 | 1 | 2005 | 45 | 0.060 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2005 | 83 | 0.060 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2005 | 66 | 0.060 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2004 | 62 | 0.060 |
Why?
| | Dinoprostone | 1 | 2004 | 187 | 0.060 |
Why?
| | Drosophila | 1 | 2005 | 142 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2010 | 3324 | 0.050 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 569 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 2757 | 0.050 |
Why?
| | Neoplasm Transplantation | 1 | 2002 | 257 | 0.050 |
Why?
| | Immunoblotting | 1 | 2002 | 301 | 0.050 |
Why?
| | Hypoxia | 1 | 2009 | 1034 | 0.050 |
Why?
| | Neoplasms, Experimental | 1 | 2002 | 169 | 0.050 |
Why?
| | Mice, Nude | 1 | 2002 | 675 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 930 | 0.040 |
Why?
| | Phosphorylation | 1 | 2005 | 1681 | 0.040 |
Why?
| | Male | 4 | 2018 | 62757 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2002 | 809 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 327 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2005 | 1037 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3168 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2003 | 844 | 0.030 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 1045 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2003 | 3936 | 0.030 |
Why?
| | Young Adult | 1 | 2010 | 12281 | 0.030 |
Why?
| | Humans | 6 | 2011 | 128019 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 24 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 52 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 20158 | 0.020 |
Why?
| | Aged | 1 | 2010 | 21892 | 0.020 |
Why?
| | Middle Aged | 2 | 2010 | 30812 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 227 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 183 | 0.020 |
Why?
| | Introns | 1 | 2011 | 249 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 262 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 245 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2011 | 443 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 638 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1241 | 0.020 |
Why?
| | Female | 3 | 2011 | 68016 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 509 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2011 | 700 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2009 | 418 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 2105 | 0.020 |
Why?
| | Prostaglandin-E Synthases | 1 | 2004 | 6 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1421 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4006 | 0.010 |
Why?
| | Hemodynamics | 1 | 2009 | 1077 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 172 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1828 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 90 | 0.010 |
Why?
| | Chronic Disease | 1 | 2009 | 1690 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 172 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 5378 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 460 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2261 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1663 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5268 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2004 | 1105 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1454 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2003 | 2258 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5199 | 0.010 |
Why?
| | Apoptosis | 1 | 2003 | 2425 | 0.010 |
Why?
|
|
Wick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|